Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.
A prospective, randomized, placebo-controlled study was conducted in a baboon model to determine if a thiazolidinedione agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone, can impede the development of endometriosis. Endometriosis was induced using laparoscopic, intrapelvic injection of eutopic menstrual endometrium, previously incubated with placebo or pioglitazone for 30 min, in 12 female baboons with a normal pelvis that had undergone at least one menstrual cycle since the time of captivity. At this point, the 12 baboons were randomized into two groups and treated from the day of induction. They received either PBS tablets (n = 6, placebo control, placebo tablets once a day by mouth) or pioglitazone (n = 6, test drug, 7.5 mg by mouth each day). A second and final laparoscopy was performed in the baboons to record the extent of endometriotic lesions between 24 and 42 d after induction (no difference in length of treatment between the two groups, P = 0.38). A videolaparoscopy was performed to document the number and surface area of endometriotic lesions. The surface area and volume of endometriotic lesions were significantly lower in pioglitazone treated baboons than the placebo group (surface area, 48.6 vs. 159.0 mm(2), respectively, P = 0.049; vol, 23.7 vs. 131.8 mm(3), respectively, P = 0.041). The surface area (3.5 vs. 17.8 mm(2), P = 0.017, pioglizatone vs. placebo) and overall number (1.5 vs. 9.5, P = 0.007, pioglizatone vs. placebo) of red lesions were lower in the pioglitazone group. A peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, effectively reduced the initiation of endometriotic disease in the baboon endometriosis model. Using this animal model, we have shown that thiazolidinedione is a promising drug for preventive treatment of endometriosis.
Lebovic
Dan I
DI
Department of Obstetrics and Gynecology, University of Wisconsin, USA. lebovic@wisc.edu
Mwenda
Jason M
JM
Chai
Daniel C
DC
Santi
Alessandro
A
Xu
Xiao
X
D'Hooghe
Thomas
T
D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D004715:Endometriosis / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D047495:PPAR gamma / Q000819:agonists*; D048530:Papio anubis; D000077205:Pioglitazone; D011446:Prospective Studies; D011897:Random Allocation; D012720:Severity of Illness Index; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones; D000077205:Pioglitazone